首页 | 本学科首页   官方微博 | 高级检索  
检索        


Efficacy and safety of long‐acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery
Authors:C Négrier  F Abdul Karim  L M Lepatan  A Lienhart  M F López‐Fernández  J Mahlangu  I Pabinger  Y Li  D Wolko  C Voigt  I Jacobs  E Santagostino
Institution:1. Centre Régional de Traitement de l'Hémophilie (CRTH)/Unite d'Hemostase Clinique, H?pital Cardiologique Louis Pradel, University Lyon I, Lyon, France;2. National Blood Centre, Kuala Lumpur, Malaysia;3. Perpetual Succour Hospital, Cebu City, Philippines;4. Complexo Hospitalario Universitario A Coruňa, A Coruňa, Spain;5. Haemophilia Clinic, Comprehensive Care Centre Charlotte Maxeke Johannesburg Academic Hospital and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa;6. NHLS South Africa, Johannesburg, South Africa;7. Clinical Division of Haematology and Haemostaseology, Medical Clinic I, Medical University Vienna, Vienna, Austria;8. Clinical Research and Development, CSL Behring, King of Prussia, PA, USA;9. A. Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Ca' Granda Foundation, Maggiore Hospital Policlinico, Milan, Italy
Abstract:
Keywords:albumin fusion proteins  factor IX  haemophilia B  orthopaedic surgery  recombinant fusion proteins
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号